## Salvatore Siena

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3679437/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer. New England Journal of Medicine, 2004, 351, 337-345.	27.0	4,721
2	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Science Translational Medicine, 2014, 6, 224ra24.	12.4	3,665
3	Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2008, 26, 1626-1634.	1.6	3,032
4	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, The, 2013, 381, 303-312.	13.7	2,276
5	Panitumumab–FOLFOX4 Treatment and <i>RAS</i> Mutations in Colorectal Cancer. New England Journal of Medicine, 2013, 369, 1023-1034.	27.0	1,971
6	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncology, The, 2010, 11, 753-762.	10.7	1,915
7	Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2007, 25, 1658-1664.	1.6	1,828
8	Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study. Journal of Clinical Oncology, 2010, 28, 4697-4705.	1.6	1,644
9	Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature, 2012, 486, 532-536.	27.8	1,605
10	Wild-Type <i>BRAF</i> Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2008, 26, 5705-5712.	1.6	1,540
11	Integrating liquid biopsies into the management of cancer. Nature Reviews Clinical Oncology, 2017, 14, 531-548.	27.6	1,375
12	Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet, The, 2014, 384, 319-328.	13.7	1,295
13	Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncology, The, 2020, 21, 271-282.	10.7	1,034
14	Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncology, The, 2005, 6, 279-286.	10.7	924
15	A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatientsâ€) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer. Cancer Discovery, 2011, 1, 508-523.	9.4	818
16	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nature Medicine, 2015, 21, 795-801.	30.7	809
17	Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti–Epidermal Growth Factor Receptor Antibody Therapies. Cancer Research, 2007, 67, 2643-2648.	0.9	801
18	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2016, 17, 738-746.	10.7	778

#	Article	IF	CITATIONS
19	<i>PIK3CA</i> Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies. Cancer Research, 2009, 69, 1851-1857.	0.9	711
20	GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR TO HARVEST CIRCULATING HAEMOPOIETIC STEM CELLS FOR AUTOTRANSPLANTATION. Lancet, The, 1989, 334, 580-585.	13.7	676
21	Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer. Journal of Clinical Oncology, 2010, 28, 1254-1261.	1.6	668
22	Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab. JAMA - Journal of the American Medical Association, 2010, 304, 1812.	7.4	663
23	Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discovery, 2017, 7, 400-409.	9.4	647
24	Amplification of the <i>MET</i> Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. Cancer Discovery, 2013, 3, 658-673.	9.4	585
25	A randomized double-blind multicenter phase III study offixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Annals of Oncology, 2003, 14, 29-35.	1.2	519
26	nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial. Journal of the National Cancer Institute, 2015, 107, dju413-dju413.	6.3	487
27	Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2009, 101, 1308-1324.	6.3	486
28	Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials. European Journal of Cancer, 2012, 48, 3082-3092.	2.8	485
29	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature, 2017, 552, 116-120.	27.8	480
30	Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Annals of Oncology, 2014, 25, 1346-1355.	1.2	462
31	High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma. New England Journal of Medicine, 1997, 336, 1290-1298.	27.0	460
32	Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i> V600E-Mutant Colorectal Cancer. Cancer Discovery, 2018, 8, 428-443.	9.4	448
33	NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open, 2016, 1, e000023.	4.5	444
34	Double-Blind, Placebo-Controlled, Randomized Phase III Trial of Darbepoetin Alfa in Lung Cancer Patients Receiving Chemotherapy. Journal of the National Cancer Institute, 2002, 94, 1211-1220.	6.3	436
35	Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution. Cancer Discovery, 2014, 4, 1269-1280.	9.4	415
36	The genomic landscape of response to EGFR blockade in colorectal cancer. Nature, 2015, 526, 263-267.	27.8	398

#	Article	IF	CITATIONS
37	Earlyâ€onset colorectal cancer in young individuals. Molecular Oncology, 2019, 13, 109-131.	4.6	365
38	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. Cancer Discovery, 2016, 6, 147-153.	9.4	338
39	Epidermal Growth Factor Receptor Gene Copy Number and Clinical Outcome of Metastatic Colorectal Cancer Treated With Panitumumab. Journal of Clinical Oncology, 2007, 25, 3238-3245.	1.6	321
40	Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials. Lancet Oncology, The, 2020, 21, 261-270.	10.7	303
41	Therapeutic Relevance of CD34 Cell Dose in Blood Cell Transplantation for Cancer Therapy. Journal of Clinical Oncology, 2000, 18, 1360-1377.	1.6	296
42	Adaptive mutability of colorectal cancers in response to targeted therapies. Science, 2019, 366, 1473-1480.	12.6	290
43	Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 Trial. European Urology, 2007, 52, 134-141.	1.9	286
44	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncology, The, 2015, 16, 937-948.	10.7	286
45	Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study. Journal of Thoracic Oncology, 2012, 7, 1823-1829.	1.1	281
46	Cell Therapy of Stage IV Nasopharyngeal Carcinoma With Autologous Epstein-Barr Virus–Targeted Cytotoxic T Lymphocytes. Journal of Clinical Oncology, 2005, 23, 8942-8949.	1.6	265
47	Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Annals of Oncology, 2007, 18, 510-517.	1.2	258
48	Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. Cancer Discovery, 2016, 6, 36-44.	9.4	258
49	HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management Forum. Oncologist, 2005, 10, 345-356.	3.7	257
50	The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. Nature Communications, 2015, 6, 7002.	12.8	251
51	EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. Cancer Discovery, 2020, 10, 1129-1139.	9.4	245
52	Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer. PLoS ONE, 2009, 4, e7287.	2.5	241
53	Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2021, 22, 779-789.	10.7	234
54	First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial. Journal of Clinical Oncology, 2012, 30, 3002-3011.	1.6	229

#	Article	IF	CITATIONS
55	Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer. Science Translational Medicine, 2014, 6, 224ra26.	12.4	228
56	Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Modern Pathology, 2015, 28, 1481-1491.	5.5	226
57	Mutant <i>KRAS</i> Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab. Journal of Clinical Oncology, 2013, 31, 759-765.	1.6	219
58	Mutations of <i>KRAS</i> and <i>BRAF</i> in Primary and Matched Metastatic Sites of Colorectal Cancer. Journal of Clinical Oncology, 2008, 26, 4217-4219.	1.6	218
59	Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer. Clinical Cancer Research, 2013, 19, 1902-1912.	7.0	214
60	Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma Journal of Clinical Oncology, 1990, 8, 768-778.	1.6	204
61	Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut, 2018, 67, 1995-2005.	12.1	188
62	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2017, 109, .	6.3	183
63	Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Annals of Oncology, 2018, 29, 1108-1119.	1.2	177
64	Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Annals of Oncology, 2017, 28, 1862-1868.	1.2	174
65	Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nature Communications, 2016, 7, 13665.	12.8	170
66	Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results Journal of Clinical Oncology, 1997, 15, 2312-2321.	1.6	168
67	Randomized Trial of Intravenous Iron Supplementation in Patients With Chemotherapy-Related Anemia Without Iron Deficiency Treated With Darbepoetin Alfa. Journal of Clinical Oncology, 2008, 26, 1619-1625.	1.6	161
68	KRAS gene amplification in colorectal cancer and impact on response to EGFRâ€ŧargeted therapy. International Journal of Cancer, 2013, 133, 1259-1265.	5.1	154
69	An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Annals of Oncology, 2008, 19, 92-98.	1.2	147
70	Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatric Blood and Cancer, 2009, 52, 767-771.	1.5	144
71	BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Annals of Oncology, 2015, 26, 2092-2097.	1.2	137
72	Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncology, The, 2008, 9, 39-44.	10.7	130

#	Article	IF	CITATIONS
73	Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). British Journal of Cancer, 2009, 101, 1261-1268.	6.4	130
74	Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. Cancer Cell, 2018, 34, 148-162.e7.	16.8	129
75	The TPM3â€NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Molecular Oncology, 2014, 8, 1495-1507.	4.6	128
76	Association of progressionâ€free survival, overall survival, and patientâ€reported outcomes by skin toxicity and <i>KRAS</i> status in patients receiving panitumumab monotherapy. Cancer, 2009, 115, 1544-1554.	4.1	127
77	Acquired resistance to EGFRâ€ŧargeted therapies inÂcolorectal cancer. Molecular Oncology, 2014, 8, 1084-1094.	4.6	121
78	Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wildâ€ŧype <scp><i>KRAS</i></scp> advanced biliary tract cancer: A randomized phase 2 trial ( <scp>V</scp> ectiâ€ <scp>BIL</scp> study). Cancer, 2016, 122, 574-581.	4.1	121
79	H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor 1² gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). Blood, 2001, 97, 3910-3918.	1.4	120
80	Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen. Cancer, 2002, 94, 2409-2415.	4.1	120
81	Rapid and complete hemopoietic reconstitution following combined transplantation of autologous blood and bone marrow cells. A changing role for high dose chemo-radiotherapy?. Hematological Oncology, 1989, 7, 139-148.	1.7	119
82	Malignant peritoneal mesothelioma—Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer, 2009, 64, 211-218.	2.0	118
83	Precision oncology in metastatic colorectal cancer — from biology to medicine. Nature Reviews Clinical Oncology, 2021, 18, 506-525.	27.6	113
84	Plasma HER2 ( <i>ERBB2</i> ) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer. Clinical Cancer Research, 2019, 25, 3046-3053.	7.0	112
85	Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2016, 108, .	6.3	111
86	Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis. Clinical Colorectal Cancer, 2017, 16, e153-e163.	2.3	110
87	Exploring the links between cancer and placenta development. Open Biology, 2018, 8, .	3.6	109
88	Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. Annals of Oncology, 2015, 26, 1994-1999.	1.2	105
89	Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anti-Cancer Drugs, 2009, 20, 616-624.	1.4	102
90	Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Annals of Oncology, 2010, 21, 348-353.	1.2	101

#	Article	IF	CITATIONS
91	Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses. JAMA Oncology, 2018, 4, e175245.	7.1	98
92	Cetuximab Plus Irinotecan in Heavily Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: MABEL Study. Journal of Clinical Oncology, 2008, 26, 5335-5343.	1.6	96
93	Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer. Clinical Cancer Research, 2013, 19, 2265-2272.	7.0	96
94	HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. Oncologist, 2019, 24, 1395-1402.	3.7	95
95	Targeted therapies: how personal should we go?. Nature Reviews Clinical Oncology, 2012, 9, 87-97.	27.6	94
96	Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. ESMO Open, 2020, 5, e000911.	4.5	94
97	Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in <i>BRAF</i> -Mutant Colorectal Cancer. Cancer Research, 2016, 76, 4504-4515.	0.9	91
98	Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Annals of Oncology, 2006, 17, 1134-1140.	1.2	84
99	Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. Annals of Oncology, 2010, 21, 655-661.	1.2	84
100	Adoptive transfer of allogeneic Epstein–Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boostsLMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. Annals of Oncology, 2004, 15, 113-117.	1.2	79
101	A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. Oncology Reports, 2003, 10, 715-24.	2.6	78
102	Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. British Journal of Cancer, 2007, 97, 1469-1474.	6.4	77
103	Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer. Journal of the National Cancer Institute, 2014, 106, djt322.	6.3	76
104	Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. Annals of Oncology, 2018, 29, 119-126.	1.2	76
105	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic <i>ROS1</i> Fusion–Positive Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2021, 39, 1253-1263.	1.6	74
106	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With <i>NTRK</i> Fusion-Positive Solid Tumors. Clinical Cancer Research, 2022, 28, 1302-1312.	7.0	74
107	High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma Journal of Clinical Oncology, 1994, 12, 503-509.	1.6	72
108	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: realâ€world results from an expanded access programme. BJU International, 2019, 123, 98-105.	2.5	70

#	Article	IF	CITATIONS
109	The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. European Journal of Cancer, 2018, 90, 63-72.	2.8	69
110	Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. Cancer Treatment Reviews, 2019, 73, 41-53.	7.7	69
111	Primary and salvage chemotherapy in advanced Hodgkin's disease: The Milan Cancer Institute experience. Annals of Oncology, 1991, 2, 9-16.	1.2	68
112	Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. European Journal of Cancer, 2015, 51, 1231-1242.	2.8	68
113	Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer. Journal of Clinical Oncology, 2016, 34, 4345-4353.	1.6	68
114	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. Clinical Cancer Research, 2020, 26, 1372-1384.	7.0	66
115	Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease. Annals of Oncology, 1991, 2, 645-653.	1.2	65
116	Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer. British Journal of Cancer, 2015, 113, 1730-1734.	6.4	65
117	Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO Open, 2022, 7, 100404.	4.5	65
118	Peripheral blood expansion of early progenitor cells after high-dose cyclophosphamide and rhGM-CSF. European Journal of Cancer & Clinical Oncology, 1991, 27, 22-27.	0.7	63
119	High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease — A 6-year update. Annals of Oncology, 1993, 4, 889-891.	1.2	61
120	Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Annals of Oncology, 2012, 23, 1185-1189.	1.2	57
121	Survival of adults treated for medulloblastoma using paediatric protocols. European Journal of Cancer, 2005, 41, 1304-1310.	2.8	56
122	Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2020, 19, 256-262.e2.	2.3	56
123	T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results. Annals of Oncology, 2012, 23, 435-441.	1.2	55
124	A Multicenter Phase II Study of AMG 337 in Patients with <i>MET</i> -Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other <i>MET</i> -Amplified Solid Tumors. Clinical Cancer Research, 2019, 25, 2414-2423.	7.0	54
125	Large-scale collection of circulating haematopoietic progenitors in cancer patients treated with high-dose cyclophosphamide and recombinant human GM-CSF. European Journal of Cancer & Clinical Oncology, 1990, 26, 562-564.	0.7	53
126	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of <i>KRAS</i> Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clinical Cancer Research, 2017, 23, 3657-3666.	7.0	53

#	Article	IF	CITATIONS
127	A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell–Intrinsic Transcriptional MSI Traits. Cancer Research, 2019, 79, 5884-5896.	0.9	53
128	Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial Journal of Clinical Oncology, 2021, 39, 3506-3506.	1.6	53
129	Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990–1999. Bone Marrow Transplantation, 2003, 32, 489-494.	2.4	52
130	Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow. Blood, 2003, 102, 3043-3051.	1.4	52
131	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the â€~BRAF BeCool' study. European Journal of Cancer, 2019, 118, 121-130.	2.8	51
132	Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. Cancer, 2005, 104, 2099-2103.	4.1	50
133	Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients Journal of Clinical Oncology, 1992, 10, 1955-1962.	1.6	48
134	Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors. Annals of Oncology, 1994, 5, 935-941.	1.2	48
135	Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy. Cancer Discovery, 2021, 11, 1923-1937.	9.4	48
136	Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial Journal of Clinical Oncology, 2013, 31, 4-4.	1.6	48
137	A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01 Journal of Clinical Oncology, 2020, 38, 4000-4000.	1.6	48
138	Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients. Cancer Discovery, 2022, 12, 1656-1675.	9.4	48
139	Improved collection of mobilized CD34+ hematopoietic progenitor cells by a novel automated leukapheresis system. Transfusion, 1999, 39, 48-55.	1.6	46
140	Reduced incidence of infusionâ€related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication. Cancer, 2010, 116, 1827-1837.	4.1	46
141	The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer. Cancers, 2021, 13, 137.	3.7	46
142	Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). Annals of Oncology, 2002, 13, 716-720.	1.2	45
143	A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. Annals of Oncology, 2008, 19, 1888-1893.	1.2	43
144	Epigenomic landscape of human colorectal cancer unveils an aberrant core of pan-cancer enhancers orchestrated by YAP/TAZ. Nature Communications, 2021, 12, 2340.	12.8	43

#	Article	IF	CITATIONS
145	Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT) versus induction Docetaxel/ Cisplatin/5-Fluorouracil (TPF) followed by CRT or CET/RT in patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck (LASCCHN). A randomized phase III factorial study (NCT01086826) Journal of Clinical Oncology, 2014, 32, 6004-6004.	1.6	43
146	No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. Annals of Oncology, 2011, 22, 1614-1621.	1.2	42
147	OA02.01 Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2018, 13, S321-S322.	1.1	42
148	Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer. Clinical Cancer Research, 2019, 25, 6243-6259.	7.0	42
149	Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer. Cancers, 2020, 12, 685.	3.7	42
150	Minimal residual disease in acute lymphoblastic leukemia detected by immune selection and gene rearrangement analysis Journal of Clinical Oncology, 1989, 7, 338-343.	1.6	41
151	EGFR FISH in colorectal cancer: what is the current reality?. Lancet Oncology, The, 2008, 9, 402-403.	10.7	41
152	Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies. Clinical Colorectal Cancer, 2018, 17, 170-178.e3.	2.3	41
153	Liquid biopsies to monitor and direct cancer treatment in colorectal cancer. British Journal of Cancer, 2022, 127, 394-407.	6.4	41
154	First-line single-agent cetuximab in patients with advanced colorectal cancer. Annals of Oncology, 2008, 19, 711-716.	1.2	40
155	Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. Digestive and Liver Disease, 2014, 46, 182-186.	0.9	40
156	Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, 80-83.	2.3	40
157	High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. Annals of Oncology, 2006, 17, 1479-1488.	1.2	39
158	<i>BRAF</i> -Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer. Clinical Cancer Research, 2020, 26, 2466-2476.	7.0	39
159	Adenovirus vectors for gene transduction into mobilized blood CD34+ cells. Gene Therapy, 1998, 5, 465-472.	4.5	38
160	Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer. ESMO Open, 2018, 3, e000353.	4.5	38
161	Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer. Cancer Treatment Reviews, 2010, 36, S1-S5.	7.7	37
162	Comprehensive analysis of <i>KRAS</i> and <i>NRAS</i> mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408) Journal of Clinical Oncology, 2013, 31, 3617-3617.	1.6	37

#	Article	IF	CITATIONS
163	Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas. Annals of Oncology, 2016, 27, 648-653.	1.2	36
164	Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors are associated with disease progression. Nature Immunology, 2021, 22, 735-745.	14.5	36
165	Tropisetron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy. European Journal of Cancer & Clinical Oncology, 1991, 27, 561-565.	0.7	35
166	Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study. Journal of Clinical Pathology, 2012, 65, 218-223.	2.0	35
167	Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. Annals of Oncology, 2016, 27, 1062-1067.	1.2	35
168	Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer. JAMA Oncology, 2022, 8, 760.	7.1	35
169	Increased incidence of colon cancer among individuals younger than 50 years: A 17 years analysis from the cancer registry of the municipality of Milan, Italy. Cancer Epidemiology, 2019, 60, 134-140.	1.9	34
170	CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions. International Journal of Molecular Sciences, 2020, 21, 6350.	4.1	34
171	Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies Journal of Clinical Oncology, 2012, 30, JBA385-JBA385	1.6	34
172	The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives. Cancer Treatment Reviews, 2022, 104, 102351.	7.7	34
173	Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anti-Cancer Drugs, 2009, 20, 616-24.	1.4	34
174	Identification and characterization of a novel <i>SCYL3-NTRK1</i> rearrangement in a colorectal cancer patient. Oncotarget, 2017, 8, 55353-55360.	1.8	33
175	Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis. Haematologica, 2006, 91, 1635-43.	3.5	33
176	Tracking aCAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor. Annals of Oncology, 2017, 28, 1302-1308.	1.2	32
177	Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. Cancers, 2021, 13, 2638.	3.7	32
178	Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study. Clinical Colorectal Cancer, 2016, 15, 213-221.	2.3	31
179	Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy Journal of Clinical Oncology, 1996, 14, 628-635.	1.6	30
180	KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment. PLoS ONE, 2011, 6, e29146.	2.5	30

#	Article	IF	CITATIONS
181	Prognostic significance of <i>K-Ras</i> mutation rate in metastatic colorectal cancer patients. Oncotarget, 2015, 6, 31604-31612.	1.8	30
182	Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor. Cytotherapy, 2012, 14, 80-90.	0.7	29
183	Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. ESMO Open, 2018, 3, e000299.	4.5	29
184	Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials. British Journal of Cancer, 2018, 119, 303-312.	6.4	29
185	A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology. Clinical Colorectal Cancer, 2019, 18, 91-101.e3.	2.3	29
186	Combined Low Densities of FoxP3+ and CD3+ Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression. Cancer Immunology Research, 2019, 7, 751-758.	3.4	29
187	Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities. Cancer Treatment Reviews, 2020, 91, 102112.	7.7	29
188	Impact of inter-reader contouring variability on textural radiomics of colorectal liver metastases. European Radiology Experimental, 2020, 4, 62.	3.4	29
189	Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer. Annals of Oncology, 2005, 16, 1848-1849.	1.2	28
190	An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer. Targeted Oncology, 2013, 8, 127-136.	3.6	28
191	Immunomodulatory Effects in a Phase II Study of Lenalidomide Combined with Cetuximab in Refractory KRAS-Mutant Metastatic Colorectal Cancer Patients. PLoS ONE, 2013, 8, e80437.	2.5	28
192	Liquid biopsy for rectal cancer: A systematic review. Cancer Treatment Reviews, 2019, 79, 101893.	7.7	28
193	Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer. Targeted Oncology, 2010, 5, 19-28.	3.6	27
194	Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents inÂmetastatic colorectal cancer patients. European Journal of Cancer, 2017, 71, 43-50.	2.8	27
195	Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials. Journal of Cancer Research and Clinical Oncology, 2018, 144, 321-335.	2.5	27
196	Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients. ESMO Open, 2019, 4, e000572.	4.5	27
197	Radiomics predicts response of individual <scp>HER2</scp> â€amplified colorectal cancer liver metastases in patients treated with <scp>HER2</scp> â€targeted therapy. International Journal of Cancer, 2020, 147, 3215-3223.	5.1	27
198	Alka-372-001: First-in-human, phase I study of entrectinib – an oral pan-trk, ROS1, and ALK inhibitor – in patients with advanced solid tumors with relevant molecular alterations Journal of Clinical Oncology, 2015, 33, 2517-2517.	1.6	27

#	Article	IF	CITATIONS
199	Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial Journal of Clinical Oncology, 2015, 33, 3508-3508.	1.6	27
200	Treatment of metastatic neuroendocrine carcinomas based on WHO classification. Anticancer Research, 2005, 25, 4463-9.	1.1	27
201	EVALUATION OF ANTIHUMAN T LYMPHOCYTE SAPORIN IMMUNOTOXINS POTENTIALLY USEFUL IN HUMAN TRANSPLANTATION. Transplantation, 1988, 46, 747-753.	1.0	26
202	Transfusion of platelet concentrates cryopreserved with ThromboSol plus low-dose dimethylsulphoxide in patients with severe thrombocytopenia: a pilot study. British Journal of Haematology, 2000, 108, 653-659.	2.5	26
203	Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. Cancer, 2013, 119, 3429-3435.	4.1	26
204	Entrectinib for the treatment of metastatic NSCLC: safety and efficacy. Expert Review of Anticancer Therapy, 2020, 20, 333-341.	2.4	26
205	Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT) Tj ETQq1	1 0 <b>47.8</b> 4314	1 r <b>gB</b> T /Over
206	Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials Journal of Clinical Oncology, 2019, 37, 3017-3017.	1.6	25
207	Selective purging by human interleukin-2 activated lymphocytes of bone marrows contaminated with a lymphoma line or autologous leukaemic cells. British Journal of Haematology, 1991, 78, 197-205.	2.5	24
208	Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR. Cancer Treatment Reviews, 2016, 51, 54-62.	7.7	24
209	A phase lb/II dose-escalation study evaluating triple combination therapy with a BRAF (encorafenib), MEK (binimetinib), and CDK 4/6 (ribociclib) inhibitor in patients (Pts) with <i>BRAF V600</i> -mutant solid tumors and melanoma Journal of Clinical Oncology, 2017, 35, 9518-9518.	1.6	24
210	Ex vivo generation and expansion of anti-tumor cytotoxic T-cell lines derived from patients or their HLA-identical sibling. International Journal of Cancer, 2004, 110, 76-86.	5.1	23
211	Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1830-1844.	1.1	23
212	Pilot evaluation of scrambler therapy for pain induced by bone and visceral metastases and refractory to standard therapies. Supportive Care in Cancer, 2016, 24, 1649-1654.	2.2	23
213	Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System. American Journal of Hypertension, 2016, 29, 158-162.	2.0	23
214	A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with <i>BRAFV600E/K</i> -mutant Solid Tumors. Clinical Cancer Research, 2020, 26, 5102-5112.	7.0	23
215	Long-term Hematopoietic Culture-initiating Cells Are More Abundant in Mobilized Peripheral Blood Grafts Than in Bone Marrow but Have a More Limited Ex Vivo Expansion Potential. Blood Cells, Molecules, and Diseases, 1996, 22, 68-81.	1.4	22
216	High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. Frontiers in Oncology, 2019, 9, 622.	2.8	22

#	Article	IF	CITATIONS
217	Present results and perspectives of allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of human solid tumors. Annals of Oncology, 2003, 14, 1177-1184.	1.2	21
218	Phase II Open-Label Study to Assess Efficacy and Safety of Lenalidomide in Combination with Cetuximab in KRAS-Mutant Metastatic Colorectal Cancer. PLoS ONE, 2013, 8, e62264.	2.5	21
219	Recombinant human interleukin-3 hastens trilineage hematopoietic recovery following high-dose (7) Tj ETQq1 1	0.784314 1.2	rgBT /Overloo
220	An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy. Lung Cancer, 2009, 64, 199-206.	2.0	20
221	Regorafenib in metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2014, 14, 255-265.	2.4	20
222	Central Nervous System as Possible Site of Relapse in <i>ERBB2</i> -Positive Metastatic Colorectal Cancer. JAMA Oncology, 2020, 6, 927.	7.1	20
223	The effect of anticonvulsant drugs on blood levels of methotrexate. Journal of Neuro-Oncology, 2000, 48, 249-250.	2.9	19
224	GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia. Cytotherapy, 2007, 9, 499-507.	0.7	19
225	Abstract CT005: Final results of the HERACLES trial in HER2-amplified colorectal cancer. Cancer Research, 2017, 77, CT005-CT005.	0.9	19
226	Optimal CD34+ Cell Dose in Autologous Peripheral-Blood Stem-Cell Transplantation. Journal of Clinical Oncology, 2000, 18, 3319-3320.	1.6	18
227	Optimising management of neutropenia and anaemia in cancer chemotherapy—advances in cytokine therapy. Critical Reviews in Oncology/Hematology, 2003, 48, S39-S47.	4.4	18
228	Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies. Nature Communications, 2018, 9, 2287.	12.8	18
229	Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations Journal of Clinical Oncology, 2014, 32, 2502-2502.	1.6	18
230	HER2 amplification as a â€~molecular bait' for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial Journal of Clinical Oncology, 2016, 34, TPS774-TPS774.	1.6	18
231	Cell-Mediated Immunity in Children with Chronic Cholestasis. Journal of Pediatric Gastroenterology and Nutrition, 1982, 1, 385-388.	1.8	17
232	High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study. Annals of Oncology, 2015, 26, 167-172.	1.2	17
233	The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review. Frontiers in Oncology, 2020, 10, 533.	2.8	17
234	Abstract CT007: Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naÃ⁻ve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results. Cancer Research, 2016, 76, CT007-CT007.	0.9	17

#	Article	IF	CITATIONS
235	Updated survival from a randomized phase III trial (MPACT) of <i>nab</i> -paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas Journal of Clinical Oncology, 2014, 32, 178-178.	1.6	17
236	OA 14.06 Entrectinib in Patients with Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2017, 12, S1783.	1.1	16
237	Human Epidermal Growth Factor Receptor 2 as a Molecular Biomarker for Metastatic Colorectal Cancer. JAMA Oncology, 2018, 4, 19.	7.1	16
238	Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond. Expert Opinion on Biological Therapy, 2021, 21, 811-824.	3.1	16
239	Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial Journal of Clinical Oncology, 2013, 31, 3636-3636.	1.6	16
240	Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation. Haematologica, 2007, 92, 418-420.	3.5	15
241	Regorafenib for metastatic colorectal cancer. Lancet, The, 2013, 381, 1537.	13.7	15
242	Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial. ESMO Open, 2016, 1, e000041.	4.5	15
243	Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience. Targeted Oncology, 2017, 12, 525-533.	3.6	15
244	Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients AgedÂ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study. Clinical Lung Cancer, 2020, 21, e567-e571.	2.6	15
245	Time course of regorafenib-associated adverse events in the phase III CORRECT study Journal of Clinical Oncology, 2013, 31, 467-467.	1.6	15
246	Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial Journal of Clinical Oncology, 2015, 33, 3558-3558.	1.6	15
247	Pneumatosis Intestinalis Induced by Anticancer Treatment: A Systematic Review. Cancers, 2022, 14, 1666.	3.7	15
248	Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC. JTO Clinical and Research Reports, 2022, 3, 100332.	1.1	15
249	Eucharistic Problems for Celiac Patients. New England Journal of Medicine, 1982, 307, 898-898.	27.0	14
250	Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA. Targeted Oncology, 2021, 16, 309-324.	3.6	14
251	Liquid Biopsy for Small Cell Lung Cancer either De Novo or Transformed: Systematic Review of Different Applications and Meta-Analysis. Cancers, 2021, 13, 2265.	3.7	14
252	Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the phase 3 DECISION trial Journal of Clinical Oncology, 2014, 32, 6060-6060.	1.6	14

#	Article	IF	CITATIONS
253	The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients Journal of Clinical Oncology, 2020, 38, TPS4124-TPS4124.	1.6	14
254	Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases. Cancers, 2022, 14, 241.	3.7	14
255	Prospective evaluation of pulmonary function in cancer patients treated with total body irradiation, high-dose melphalan, and autologous hematopoietic stem cell transplantation. International Journal of Radiation Oncology Biology Physics, 1990, 19, 743-749.	0.8	13
256	Iron supplementation and erythropoiesisâ€stimulatory agents in the treatment of cancer anemia. Cancer, 2009, 115, 1169-1173.	4.1	13
257	Magnetic Resonance Imaging as an Early Indicator of Clinical Outcome in Patients With Metastatic Colorectal Carcinoma Treated With Cetuximab or Panitumumab. Clinical Colorectal Cancer, 2013, 12, 45-53.	2.3	13
258	Toxicity of oxaliplatin rechallenge in metastatic colorectal cancer. Annals of Oncology, 2018, 29, 2143-2144.	1.2	13
259	Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies. ESMO Open, 2020, 5, e000867.	4.5	13
260	A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment. Investigational New Drugs, 2020, 38, 1774-1783.	2.6	13
261	Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study. BMC Cancer, 2012, 12, 158.	2.6	12
262	TRKA expression and <i>NTRK1</i> gene copy number across solid tumours. Journal of Clinical Pathology, 2018, 71, 926-931.	2.0	12
263	Combined negative and positive selection of mobilized CD34 + blood cells. British Journal of Haematology, 1996, 94, 716-721.	2.5	11
264	Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000ÂIU administered once-weekly. Supportive Care in Cancer, 2007, 15, 1057-1066.	2.2	11
265	Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trials. Quality of Life Research, 2016, 25, 2645-2656.	3.1	11
266	Optimized EGFR Blockade Strategies in <i>EGFR</i> Addicted Gastroesophageal Adenocarcinomas. Clinical Cancer Research, 2021, 27, 3126-3140.	7.0	11
267	GAIN-(C): Efficacy and safety analysis of imgatuzumab (GA201), a novel dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with FOLFIRI compared to cetuximab plus FOLFIRI in second-line KRAS exon 2 wild type (e2WT) or with FOLFIRI alone in mutated (e2MT) metastatic colorectal cancer (mCRC) Journal of Clinical Oncology,	1.6	11
268	Does escalation results from phase Ib/II Norse study of erdafitinib (ERDA) + PD-1 inhibitor JNJ-63723283 (Cetrelimab [CET]) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and selected fibroblast growth factor receptor (FGFR) gene alterations Journal of Clinical Oncology, 2020, 38, 511-511.	1.6	11
269	Cetuximab for treatment of metastatic colorectal cancer. Annals of Oncology, 2006, 17, vii66-vii67.	1.2	10
270	Linitis Plastica of the Rectum As a Clinical Presentation of Metastatic Lobular Carcinoma of the Breast. Journal of Clinical Oncology, 2016, 34, e54-e56.	1.6	10

#	Article	IF	CITATIONS
271	Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial Journal of Clinical Oncology, 2019, 37, TPS2659-TPS2659.	1.6	10
272	SPECIFIC EX-VIVO DEPLETION OF HUMAN BONE MARROW T LYMPHOCYTES BY AN ANTI-PAN-T CELL (CD5) RICINA-CHAIN IMMUNOTOXIN. Transplantation, 1987, 43, 491.	1.0	9
273	Clinical utilisation of human haematopoietic progenitors elicited in peripheral blood by recombinant human granulocyte colony-stimulating factor (rHuG-CSF). European Journal of Cancer, 1994, 30, 235-238.	2.8	9
274	Imaging and clinical correlates with regorafenib in metastatic colorectal cancer. Cancer Treatment Reviews, 2020, 86, 102020.	7.7	9
275	Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study. Cancers, 2022, 14, 1197.	3.7	9
276	Mobilization of peripheral blood progenitor cells for autografting: chemotherapy and G-CSF or GM-CSF. Best Practice and Research in Clinical Haematology, 1999, 12, 27-39.	1.7	8
277	Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1783-1793.	2.5	8
278	Mutant (MT) <i>KRAS</i> codon 12 and 13 alleles in patients (pts) with metastatic colorectal cancer (mCRC): Assessment as prognostic and predictive biomarkers of response to panitumumab (pmab) Journal of Clinical Oncology, 2012, 30, 383-383.	1.6	8
279	Second-Line Chemotherapy with Bleomycin, Methotrexate, and Vinorelbine (BMV) for Patients with Squamous Cell Carcinoma of the Head, Neck and Esophagus (SCC-HN&E) Pretreated with a Cisplatin-Containing Regimen: A Phase II Study. Journal of Chemotherapy, 2003, 15, 394-399.	1.5	7
280	Entrectinib in NTRK-fusion positive gastrointestinal cancers: integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1, and ALKA-372-001). Annals of Oncology, 2019, 30, iv134.	1.2	7
281	Breaking Barriers in HER2+ Cancers. Cancer Cell, 2020, 38, 317-319.	16.8	7
282	Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification) Journal of Clinical Oncology, 2013, 31, TPS3648-TPS3648.	1.6	7
283	Establishment and characterization of a new Ewing's sarcoma cell line from a malignant pleural effusion. Anticancer Research, 2007, 27, 3273-8.	1.1	7
284	Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status. Clinical Colorectal Cancer, 2018, 17, 50-57.e8.	2.3	6
285	Personalized therapeutic strategies in HER2-driven gastric cancer. Gastric Cancer, 2021, 24, 897-912.	5.3	6
286	Abstract LB-174: Use of massively parallel, next-generation sequencing to identify gene mutations beyondERASthat predict response to panitumumab in a randomized, phase 3, monotherapy study of metastatic colorectal cancer (mCRC). , 2010, , .		6
287	Cetuximab/radiotherapy (CET+RT) versus concomitant chemoradiotherapy (cCHT+RT) with or without induction docetaxel/cisplatin/5-fluorouracil (TPF) in locally advanced head and neck squamous cell carcinoma (LASCCHN): Preliminary results on toxicity of a randomized, 2x2 factorial, phase II-III study (NCT01086826) Journal of Clinical Oncology 2012, 30, 5513-5513	1.6	6
288	Final skin toxicity (ST) and patient-reported outcomes (PRO) results from PRIME: A randomized phase III study of panitumumab (pmab) plus FOLFOX4 (CT) for first-line metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2012, 30, 531-531.	1.6	6

#	Article	IF	CITATIONS
289	Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial Journal of Clinical Oncology, 2014, 32, 6061-6061.	1.6	6
290	Hepatitis B and acute lymphoblastic leukemia. Journal of Pediatrics, 1982, 101, 156.	1.8	5
291	Total body irradiation and high-dose melphalan with bone marrow transplantation at Istituto Nazionale Tumori, Milan, Italy. Radiotherapy and Oncology, 1990, 18, 105-109.	0.6	5
292	Clinical implications of the heterogeneity of hematopoietic progenitors elicited in peripheral blood by anticancer therapy with cyclophosphamide and cytokine(s). Stem Cells, 1993, 11, 72-75.	3.2	5
293	Genetic Idiotypic and Tumor Cell-Based Vaccine Strategies for Indolent Non Hodgkins Lymphoma. Current Gene Therapy, 2005, 5, 511-521.	2.0	5
294	Incidence of Human Cytomegalovirus Infection in Patients with Refractory Solid Tumors Receiving Nonmyeloablative Allogeneic Stem Cell Transplants versus Recipients of Standard SCT for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2005, 11, 423-428.	2.0	5
295	Controversial evaluation of EGFR protein and gene status in predicting response to anti-EGFR monoclonal antibodies in metastatic colorectal cancer: a case report and review of the literature. Targeted Oncology, 2008, 3, 127-130.	3.6	5
296	Antitumor effect of allogeneic hematopoietic SCT in metastatic medulloblastoma. Bone Marrow Transplantation, 2008, 42, 131-133.	2.4	5
297	Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids. JCO Precision Oncology, 2021, 5, 1192-1199.	3.0	5
298	Allogeneic blood stem cell transplantation after a reducedâ€intensity, preparative regimen. Cancer, 2002, 94, 2409-2415.	4.1	5
299	Abstract 5723: Inactivation of DNA repair triggers neoantigen generation and impairs tumor growth. Cancer Research, 2018, 78, 5723-5723.	0.9	5
300	Abstract CT192: Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2. , 2019, , .		5
301	Expansion of Immunostimulatory Dendritic Cells from Peripheral Blood of Patients with Cancer. Oncologist, 1997, 2, 65-69.	3.7	5
302	Application of histology-agnostic treatments in metastatic colorectal cancer. Digestive and Liver Disease, 2022, 54, 1291-1303.	0.9	5
303	Practical aspects of flow cytometry to guide large-scale collection of circulating hematopoietic progenitors for autologous transplantation in cancer patients. International Journal of Cell Cloning, 1992, 10, 26-29.	1.6	4
304	Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer. Annals of Oncology, 2006, 17, ii49-ii51.	1.2	4
305	Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET). Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 114-116.	1.5	4
306	Analysis of metabolic response (MR) by positron emission tomography (PET) compared with tumor response by computed tomography (CT) from MPACT, a phase III trial comparing nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone for patients (pts) with metastatic adenocarcinoma of the pancreas Journal of Clinical Oncology, 2014, 32, 254-254.	1.6	4

#	Article	IF	CITATIONS
307	Aspirin for colorectal cancer with PIK3CA mutations: the rising of the oldest targeted therapy?. Annals of Translational Medicine, 2013, 1, 12.	1.7	4
308	High Sensitivity and Specificity Assay for Detection of Leukemia/Lymphoma Cells in Human Bone Marrow. Annals of the New York Academy of Sciences, 1987, 511, 473-482.	3.8	3
309	A Case of Metastatic Axillary Lymph Nodes Involvement from Unknown Primary Cancer: Clinical Usefulness of [99mTc]-Sestamibi. Tumori, 1998, 84, 612-613.	1.1	3
310	Iron Supplementation during Treatment with Erythropoiesis-Stimulating Agents for Cancer-Related Anemia. Chemotherapy, 2008, 54, 417-420.	1.6	3
311	Overall Survival (OS) and Tumour Shrinkage Outcomes in Patients with Symptomatic/Asymptomatic Metastatic Colorectal Cancer (MCRC): Data From the Prime Study. Annals of Oncology, 2013, 24, iv32.	1.2	3
312	Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer. ESMO Open, 2016, 1, e000079.	4.5	3
313	Chemotherapy-induced myasthenic crisis in thymoma treated with primary chemotherapy with curative intent on mechanical ventilation: a case report and review ofÂthe literature. Journal of Medical Case Reports, 2021, 15, 32.	0.8	3
314	Abstract CT082: Pertuzumab and trastuzumab-emtansine in HER2-positive colorectal cancer: the HERACLES B trial. , 2016, , .		3
315	Final results of a randomized, double-blind, phase II study of gemcitabine plus vandetanib or plus placebo in the treatment of advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) elderly patients (ZELIG study NCT00753714) Journal of Clinical Oncology, 2012, 30, 7550-7550.	1.6	3
316	The GAIN-C study (BP25438): Randomized phase II trial of RG7160 (GA201) plus FOLFIRI, compared to cetuximab plus FOLFIRI or FOLFIRI alone in second-line KRAS wild type (WT) or mutant metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2012, 30, TPS3637-TPS3637.	1.6	3
317	Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib Journal of Clinical Oncology, 2013, 31, 381-381.	1.6	3
318	Concomitant blockade of EGFR and MEK overcomes acquired resistance to anti-EGFR therapy in colorectal cancer cells and patients' avatars Journal of Clinical Oncology, 2014, 32, 2626-2626.	1.6	3
319	Survival outcomes in patients (pts) with <i>KRAS/NRAS</i> ( <i>RAS</i> ) wild-type (WT) metastatic colorectal cancer (mCRC) and non-liver-limited disease (non-LLD): Data from the PRIME study Journal of Clinical Oncology, 2014, 32, 3550-3550.	1.6	3
320	Clinicopathological characteristics and HER2 status in metastatic colorectal cancer patients: Results of a diagnostic model development study Journal of Clinical Oncology, 2018, 36, 581-581.	1.6	3
321	Palliative treatment for elderly patients with colon cancer in ten Italian medical oncology units. Anticancer Research, 2008, 28, 1813-20.	1.1	3
322	Re: Randomized Trial of High-Dose Chemotherapy and Blood Cell Autografts for High-Risk Primary Breast Carcinoma. Journal of the National Cancer Institute, 2000, 92, 1271-1272.	6.3	2
323	Imaging in nasopharyngeal carcinoma: the value of 18-Florine Fluorodeoxyglucose PET/CT in comparison to conventional imaging modalities CT and MRI. Radiology and Oncology, 2009, 43, .	1.7	2
324	Pertuzumab and trastuzumab-emtansine in HER2 positive metastatic colorectal cancer: the HERACLES B TRIAL. Annals of Oncology, 2016, 27, iv47.	1.2	2

#	Article	IF	CITATIONS
325	Impact of primary tumour location on response and resection outcomes in patients with metastatic colorectal cancer (mCRC) undergoing first-line treatment. Annals of Oncology, 2017, 28, iii113-iii114.	1.2	2
326	A phase II, open-label, randomized clinical trial of panitumumab plus gemcitabine and oxaliplatin (GEMOX) versus GEMOX alone as first-line treatment in advanced biliary tract cancer: The Vecti-BIL study Journal of Clinical Oncology, 2015, 33, 281-281.	1.6	2
327	Therapeutic dual inhibition of HER2 pathway for metastatic colorectal cancer (mCRC): The HERACLES trial Journal of Clinical Oncology, 2015, 33, 565-565.	1.6	2
328	Quality of life (QoL) during first-line treatment with FOLFOX4 with or without panitumumab (pmab) in RAS wild-type (WT) metastatic colorectal carcinoma (mCRC) Journal of Clinical Oncology, 2015, 33, 693-693.	1.6	2
329	Amplification of the MET receptor to drive resistance to anti-EGFR therapies in colorectal cancer Journal of Clinical Oncology, 2013, 31, 11005-11005.	1.6	2
330	Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III MPACT study of <i>nab</i> -paclitaxel ( <i>nab</i> -P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC) Journal of Clinical Oncology, 2014, 32, 4027-4027.	1.6	2
331	Iron Supplement in Cancer Patients Receiving Erythropoietin. Journal of Clinical Oncology, 2004, 22, 4428-4428.	1.6	1
332	Evidence of graft-versus-tumour effect following allogeneic haematopoietic stem cell transplantation in renal cancer other than clear cell type. Bone Marrow Transplantation, 2004, 34, 917-918.	2.4	1
333	Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia. Future Oncology, 2006, 2, 667-676.	2.4	1
334	Response: Re: Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2010, 102, 573-575.	6.3	1
335	Reply to E. Hawkes et al. Journal of Clinical Oncology, 2010, 28, e532-e533.	1.6	1
336	Cardiotoxicity of novel molecular targeted therapies of cancer. Journal of Cardiovascular Echography, 2011, 21, 78-85.	0.4	1
337	Is Codon 13 KRAS Mutation Biologically Different from Codon 12 Mutation?. Current Colorectal Cancer Reports, 2012, 8, 272-276.	0.5	1
338	O-0023 Phase 3 Correct Trial of Regorafenib in Metastatic Colorectal Cancer (mCRC). Annals of Oncology, 2012, 23, iv15-iv16.	1.2	1
339	Interim Analysis Results of Above Phase II Study with Bevacizumab in Patients with Initially not Resectable/Borderline Resectable Colorectal Liver-Limited Metastases. Annals of Oncology, 2013, 24, iv108.	1.2	1
340	Importance of tumour symptoms and extent of disease on efficacy of first-line FOLFOX4 ± panitumumab (pmab) in patients (pts) with RAS wild-type (WT)/BRAF WT metastatic colorectal cancer (mCRC) in the PRIME study. Annals of Oncology, 2016, 27, vi159.	1.2	1
341	Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer. Handbook of Experimental Pharmacology, 2017, 249, 145-159.	1.8	1
342	The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer. JAMA Oncology, 2019, 5, 1510.	7.1	1

#	Article	IF	CITATIONS
343	Abstract 878: Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. , 2016, , .		1
344	Quality of life maintained on the ziv-aflibercept/FOLFIRI regimen: Third interim analysis of the global aflibercept safety and HR-QOL program Journal of Clinical Oncology, 2014, 32, e14560-e14560.	1.6	1
345	Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program in pts pretreated with bevacizumab (B) Journal of Clinical Oncology, 2014, 32, 556-556.	1.6	1
346	Phase II study of temozolomide (TMZ) in metastatic colorectal cancer (mCRC) patients molecularly selected by MGMT promoter hypermethylation Journal of Clinical Oncology, 2015, 33, 583-583.	1.6	1
347	Abstract A57: Extended RAS analysis in patients (pts) with untreated metastatic colorectal cancer (mCRC): Results from the PRIME and PEAK studies. , 2014, , .		1
348	Abstract 2848: Radiographic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer. , 2018, , .		1
349	Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation. ESMO Open, 2020, 5, e000860.	4.5	1
350	A CUP OF COFFEE FOR ALLERGIC RHINITIS. Lancet, The, 1982, 319, 1133.	13.7	0
351	Hematopoietic stem cell transplantation in the treatment of lymphoma. Current Opinion in Oncology, 1991, 3, 838-842.	2.4	0
352	Absence ofc-Kit and members of the epidermal growth factor receptor family in refractory germ cell cancer. Cancer, 2003, 97, 2926-2927.	4.1	0
353	Epidermal Growth Factor Receptor-Targeted Therapy of Colorectal Cancer with Panitumumab. Current Cancer Therapy Reviews, 2007, 3, 249-254.	0.3	0
354	PD-0023 Benefit of Adding Panitumumab (pmab) To 1St/2Nd-Line Chemotherapy in Patients with KRAS WT mCRC: A Number-Needed-To-Treat (NNT) Analysis. Annals of Oncology, 2012, 23, iv26-iv27.	1.2	0
355	Evaluation of KRAS, NRAS, and BRAF Mutations in Prime: Panitumumab with FOLFOX4 as First-Line Treatment in Metastatic Colorectal Cancer (MCRC). Annals of Oncology, 2013, 24, iv23-iv24.	1.2	0
356	The FUNNEL: a precision medicine project for metastatic colorectal cancer. Annals of Oncology, 2016, 27, iv48.	1.2	0
357	Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase 3b CONSIGN trial. Annals of Oncology, 2016, 27, iv44.	1.2	0
358	The right chance for temozolomide in metastatic colorectal cancer?. Annals of Oncology, 2018, 29, 1618-1619.	1.2	0
359	SP-0453 Targeting DNA repair to improve immunesurveillance and restrict cancer growth. Radiotherapy and Oncology, 2019, 133, S235-S236.	0.6	0
360	Indicators of guideline-concordant care in lung cancer defined with a modified Delphi method and piloted in a cohort of over 5,800 cases. Archives of Public Health, 2021, 79, 12.	2.4	0

#	Article	IF	CITATIONS
361	Abstract B229: Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. , 2009, , .		0
362	Abstract LB-220: Translational research with RG7160 (GA201) leads to a phase II clinical study in combination with FOLFIRI in 2ndline metastatic colorectal cancer (mCRC). , 2012, , .		0
363	Abstract LB-75: Blood-based molecular detection of acquired resistance to anti-ECFR therapies in colorectal cancer patients , 2013, , .		О
364	Impact of IVS14+1G>A and 2846A>T DPYD polymorphisms on toxicity outcome of patients treated with fluoropyrimidine-containing regimens Journal of Clinical Oncology, 2013, 31, 11058-11058.	1.6	0
365	Survival outcomes in the PRIME study for patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC), by baseline Eastern Cooperative Oncology Group (ECOG) performance status (PS) Journal of Clinical Oncology, 2014, 32, 3557-3557.	1.6	Ο
366	Safety and tolerability of regorafenib (REG) in Italian patients: Subgroup analysis of the phase III CORRECT study in metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2014, 32, e14613-e14613.	1.6	0
367	Abstract 2829: Identification of the role of SRBC methylation-associated gene silencing as predictive factor of oxaliplatin secondary resistance in metastasic colorectal cancer patients. , 2014, , .		Ο
368	Prognostic significance of KRAS mutation rate in metastatic colorectal cancer (mCRC) patients (pts) Journal of Clinical Oncology, 2015, 33, e22075-e22075.	1.6	0
369	Abstract 616: Blood-based molecular landscapes of resistance to EGFR blockade in colorectal cancer patients. , 2015, , .		Ο
370	Clonal evolution and drug resistance in the blood of patients with metastatic solid tumors responding to targeted therapies: The CORNUCOPIA study Journal of Clinical Oncology, 2016, 34, TPS11615-TPS11615.	1.6	0
371	The FUNNEL: A molecular multiplex triage for precision medicine in metastatic colorectal cancer Journal of Clinical Oncology, 2016, 34, TPS3636-TPS3636.	1.6	О
372	Clinical and molecular landscape of metastatic colorectal cancer (mCRC) harboring ALK, ROS1, or NTRK 1, 2, 3 (NTRKs) rearrangements Journal of Clinical Oncology, 2017, 35, 589-589.	1.6	0
373	Abstract 3834: Tracking CAD-ALK gene translocation in urine and plasma of a colorectal cancer patient treated with ALK blockade. , 2017, , .		Ο
374	Abstract 2913: Emergence ofRASorEGFRmutant clones affects duration of response to EGFR blockade in colorectal cancers. , 2017, , .		0
375	Abstract 2743: Accumulation of predicted neoantigens by MMR deficiency triggered by temozolomide treatment of human colorectal cancer. , 2018, , .		Ο
376	Abstract 205: Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies. , 2018, , .		0
377	Mutational signatures of early-onset colorectal cancer Journal of Clinical Oncology, 2019, 37, e15113-e15113.	1.6	0
378	Radiomics features on CT scans to predict response to HER2-targeted therapy of hepatic metastases from colorectal cancer Journal of Clinical Oncology, 2019, 37, e15086-e15086.	1.6	0

#	Article	IF	CITATIONS
379	Abstract LB-299: A comprehensive platform of patient-derived xenografts and matched cell lines mirrors the genomic landscape of colorectal cancer. , 2019, , .		0
380	Abstract CT214: AlfaOmega- a master protocol empowering precision research in colorectal cancer. , 2019, , .		0
381	Abstract CT215: Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer. , 2019, , .		0
382	Efficacy of retreatment with oxaliplatin-based regimens in metastatic colorectal cancer patients: The RETROX-CRC retrospective study Journal of Clinical Oncology, 2022, 40, 127-127.	1.6	0
383	Therapeutic targeting of epidermal growth factor receptor with monoclonal antibodies. I Supplementi Di Tumori, 2002, 1, S46-8.	0.1	0
384	Neuroimaging abnormalities in adult medulloblastoma undergoing intensified therapy. Anticancer Research, 2008, 28, 3991-2.	1.1	0
385	Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials. Current Opinion in Molecular Therapeutics, 2010, 12, 703-11.	2.8	0